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ABSTRACT: Multifunctionalized biomaterials with enhanced bone antiresorptive properties were obtained through 
adsorption of a bisphosphonate, risedronate, on hydroxyapatite (HA) nanocrystals functionalized with zinc ions and 
polyethylenimine (PEI). Zn incorporation into the HA structure amounts to about 8 a tom %, whereas the PEI content of the 
bifunctionalized material ZnHAPEIBP is about 5.9 wt %. The mechanism of adsorption and release of the bisphosphonate on 
ZnHAPEI is compared with that on ZnHA risedronate adsorption isotherm on ZnHA is a Langmuir type, whereas the 
isotherm of adsorption on ZnHAPEI is better fitted with a Freundlich mode! and involved a higher amount of adsorbed 
risedronate. ln vitro ce!! tests were carried out with a coculture mode! of osteoblasts and osteoclasts using a mode! simulating 
oxidative stress and consequent cellular senescence and osteoporosis by the addition of H202. The conditions utilized in the 
coculture mode! strongly affect osteoblast behavior. The results show that the composite materials allow an increase in 
osteoblast viability and recover impairment, revealing a nove! characteristic of risedronate that is able to counteract the negative 
effects of oxidative stress when associated with differently functionalized samples. Both PEI and the bisphosphonate reduce 
osteoclast viability. Moreover, PEI, and even more risedronate, exerts an inhibitory effect on osteoclast activity. 
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■ INTRODUCTION
Bone tissue is a composite material where the inorganic phase 
is embedded in an organic matrix, mainly constituted of type I 
collagen. 1 The inorganic phase is a calcium phosphate which is 
described as a nonstoichiometric hydroxyapatite (HA), 
characterized by small crystal dimensions and a low degree 
of crystallinity.2,3 Because of their similarity to the inorganic 
phase of bone, synthetic calcium phosphates (CaPs), and in 
particular HA, are widely employed for the preparation of 
biomaterials aimed to treat disorders of the musculoskeletal 
system. Functionalization with biologically active ions, 
molecules, and drugs can greatly improve the biological 
performance of CaPs based materials and opens new possible 
applications in the biomedical field.415 In particular, CaPs have 
been proposed as delivery systems for the local release of 
bisphosphonates (BPs).6'7 Bisphosphonates include several
DOi: 10.1021/acsbianaterial�9b00795  
molecules sharing a common backbone structure, where a
carbon atom bonds two phosphonate groups and diﬀering in
the two side chains which complete the tetravalence of carbon.
These drugs are usefully employed for the treatment of
pathologies associated with abnormally high bone resorption,
including osteoporosis, Paget’s disease, multiple myeloma, and
bone metastases.6−10 However, BPs display several negative
characteristics, such as low bioavailability, and important side
eﬀects due of oversuppression of bone resorption,11 including
osteonecrosis of the jaw and atypical subtrochanteric femoral
fractures.10,12−14 The use of CaPs, as well as of other materials,
as delivery systems for BPs has been proposed as a strategy to
provide local administration of these drugs and reduce the
doses of systemic administration and related side eﬀects.10,11
The binding aﬃnity of BPs to hydroxyapatite depends on the
chemistry of their side chains.15 On the other hand, the
structure and chemistry of the apatitic surface inﬂuence the
parameters of adsorption of BPs, and their release kinetics as
the main reaction is an ion exchange process (chemisorption)
between BPs in solution and phosphate ions on the apatite
crystal surface.16−19 Previous papers show that higher amounts
of BPs were adsorbed on nanocrystalline apatites (NCA)
compared to well crystalline stoichiometric HA, which has
been explained by the NCA surface composition rich in labile
species able to be exchanged and the higher speciﬁc surface
area of the nanocrystals. Similarly, the maturation time of NCA
inﬂuences the development of the surface hydrated layer and
its composition: immature apatitic samples exhibit higher
amounts of BPs both adsorbed and released compared with
matured apatitic crystals.18 We have previously shown that a
partial substitution of the Zn2+ ion to the Ca2+ ion into the HA
structure provokes just minor variations in the mechanisms of
adsorption (chemisorption) and release of the risedronate.19
On the other hand, functionalization of HA with a cationic
polymer, polyethylenimine (PEI), modiﬁes the interactions
with risedronate, so that its adsorption implies not just
chemisorption but also physisorption, which also inﬂuences its
release.19 The structures of risedronate and of PEI are reported
in Supporting Information (Scheme S1). Zinc substituted
hydroxyapatite was shown to inhibit osteoclast proliferation
and activity.20 Similarly, zinc substituted tricalcium phosphate
was reported to reduce osteoclast number and activity in
vitro.21 Moreover, zinc containing calcium phosphates pos
itively inﬂuence osteoblast response: the presence of zinc in
the apatite layer deposited on Ti external ﬁxation rods
increased osteoblast proliferation and diﬀerentiation in
vitro.22 Furthermore, a zinc containing calcium phosphate
cement implanted in the femora and tibia of rabbits was shown
to promote new bone formation around the implants.23 In the
present work, we developed multifunctionalized materials able
to add the downregulating eﬀect of zinc on osteoclastogenesis
and osteoclast activity to the antiresorptive properties of
risedronate.20−25 To this aim, Zn substituted hydroxyapatite
was functionalized with PEI (ZnHAPEI). The double
functionalization should increase the amount of adsorbed
risedronate, thanks to the presence of the polycationic polymer
on the surface of the crystals of the composite material. The
inﬂuence of PEI on the adsorption and release mechanisms of
risedronate on/from ZnHAPEI was evaluated by comparing
the results with those obtained on zinc substituted hydrox
yapatite (ZnHA). Coculture systems with osteoblasts and
osteoclasts, are a useful in vitro model for biomaterial testing,
as they mimic the human physiological microenvironment in
the complex process of bone formation and resorption. As the
functionalized biomaterials should aﬀect both osteoblast and
osteoclast behavior, bone cells’ response to the materials with
and without adsorbed risedronate was tested in vitro using a
coculture model of osteoblast (OB) and osteoclast (OC)
added with hydrogen peroxide (H2O2), in order to increase the
generation of reactive oxygen species (ROS) and simulate in
vitro the condition of cellular senescence and osteoporosis.
■ MATERIALS AND METHODS
Synthesis of the Apatitic Samples. The synthesis of zinc
substituted hydroxyapatite (ZnHA) was carried out in N2 atmosphere
using CO2 free distilled water.
19 A total of 50 mL of a solution
containing Ca(NO3)2·4H2O and Zn(NO3)2·6H2O with 1.08 M total
cationic concentration, and a Zn/(Ca + Zn) molar ratio of 0.1 (pH
adjusted to 10 with NH4OH) was heated at 90 °C. Dropwise addition
of 50 mL of 0.65 M (NH4)2HPO4 solution under stirring led to the
fast formation of a precipitate, which was separated from the reaction
solution after 5 h of maturation at 90 °C under stirring through
centrifugation at 10 000 rpm for 10 min. Then, the solid product was
repeatedly washed with CO2 free distilled water and dried at 37 °C
overnight.
Adsorption of polyethylenimine (PEI, Sigma, MW ≅ 2000 g
mol−1) on the as prepared ZnHA was performed by soaking ZnHA
powder (100 mg) in an aqueous solution of 4 M PEI, under stirring
for 24 h. Then, the solid was centrifuged at 10 000 rpm for 10 min
and washed with deionized water. Finally, the powder was dried at 37
°C, and the sample was labeled as ZnHAPEI.
Risedronate Adsorption and Release. Adsorption experiments
were carried out in triplicate on ZnHA and ZnHAPEI by dispersing
50 mg of powder in 5 mL of adsorption medium, an aqueous solution
of risedronate (Aldrich, from 0 to 3 mM in 1 mM KCl solution at
physiological pH 7.4 adjusted by addition of HCl or KOH solution)
in a polyethylene tube. After sonication for 1 min, the suspensions
were incubated for 1 h at physiological temperature (37 ± 1 °C)
without stirring. After centrifugation for 10 min at 5000 rpm, the
supernatants obtained were ﬁltrated onto 0.2 μm Millipore ﬁlters, and
these solutions were stored in a refrigerator at 4 °C before titration.
The solids were washed with deionized water and dried at 37 °C
overnight before their characterization. The solids at maximum
risedronate content reached in this work (1.2 and 1.5 μmol/m2 for
ZnHA and ZnHAPEI respectively) were labeled ZnHABP and
ZnHAPEIBP.
The supernatants after adsorption were analyzed for risedronate
and phosphate content. Risedronate concentration was determined by
UV spectrophotometric absorption at 262 nm (Hewlett Packard
8452A diode array spectrophotometer), corresponding to the
maximum absorbance of the pyridine group of the risedronate
molecule. Phosphorus concentration was determined by inductively
coupled plasma atomic emission spectroscopy (ICP AES, Horiba
Jobin Yvon).
The release proﬁles of risedronate were recorded using a
ﬂowthrough cell system (USP Apparatus 4 Sotax CE6, Sotax AG,
Switzerland) with 12 mm cells for powders and a peristaltic pump. In
all experiments, laminar ﬂow was used with one glass beads layer
covered with each sample, mixed with 2 g of glass beads. The analyses
were performed utilizing diﬀerent quantities of the tested materials so
that the amount of adsorbed BP was the same (about 1.8 μmol) in all
the examined samples, ZnHA and ZnHAPEI. The European
Pharmacopeia guidelines were followed for the release tests, which
were performed at 37.0 ± 0.5 °C under sink conditions using
deionized water pumped through the column at a ﬂow rate of 9 mL/
min. A closed system was used, recycling 50 mL of release medium.
Periodically, fractions of 5 mL were collected for determination of
risedronate content by UV spectrophotometry at 262 nm. After each
sampling, the same volume of release medium was replaced back in
the cell system. Each release test was performed in triplicate. The
results are presented as cumulated BP release (%) proﬁles as a
function of time.
Solid Samples Characterization. Elemental analyses were
performed by means of an inductively coupled plasma (ICP) mass
spectrometer (ICP AES, Horiba Jobin Yvon) on powders previously
dissolved in 0.6 M HNO3 solution.
X ray diﬀraction analysis was carried out by means of a PANalytical
X’Pert PRO powder diﬀractometer equipped with a fast X’Celerator
detector. Cu Kα radiation was used (40 mA, 40 kV). The 2θ range
was from 10° to 60° with a step size of 0.1° and time/step of 100 s.
The lattice parameters were determined by least squares reﬁnements
from the well determined positions of the most intense reﬂections
using the HighScore Plus software package (PANalytical). The peak
broadening was used to evaluate the crystal size (τhkl), which was
calculated from the width at half maximum intensity (β1/2) using the
Scherrer equation:
τ λ
β θ
= K
coshkl 1/2 (1)
where λ is the wavelength, θ the diﬀraction angle, and K a constant
depending on crystal habit (chosen as 0.9).
Morphological investigation was performed using a Philips CM100
transmission electron microscope, operating at 80 kV. A drop of
sonicated sample suspension in ethanol was transferred onto Formvar
ﬁlms supported on conventional copper microgrids.
Thermogravimetric analysis was performed by means of a
PerkinElmer TGA 7. Samples (5−10 mg) were examined in a
platinum crucible in air ﬂow (20 cm3/min) at a rate of 10 °C/min up
to 800 °C. Results represent the mean value of weight losses
measured for three diﬀerent samples.
Zeta potential was measured using a Malvern Instruments Zetasizer
Nano. For the analysis, which was performed in triplicate, 5 mg of
powder sample was suspended in 50 mL of Milli Q water and
sonicated for 2 min.
The speciﬁc surface area was measured using a Carlo Erba Sorpty
1750 BET analyzer using constant volume N2 adsorption with
desorption at 80 °C.
Raman spectroscopy was performed using a Horiba, Jobin Yvon
Labram HR800 confocal microspectrometer with a helium−neon
laser (632.82 nm) over a wavelength range of 400−4000 cm−1. The
spectral resolution was 2 cm−1, the laser power was 2 mW, and
integration times varied from 30 to 120 s. Three spectral
accumulations were averaged.
In Vitro Coculture Model. In vitro tests were carried out on disk
shaped samples (Ø = 6.0 mm). Each disk was prepared by pressing 40
mg of powder into cylindrical molds by using a standard evacuable
pellet die (Hellma).
AFM analysis of the disk shaped samples was performed using a
Veeco Nanoscope 3D instrument. The samples were analyzed in
tapping mode using an E scanner (maximum scan size 15 μm) and
phosphorus (n) doped silicon probes (spring constant 20−80 N/m;
resonance frequency 250−290 kHz; nominal tip radius < 10 nm).
Before in vitro tests, the samples were sterilized using γ rays
(Cobalt 60) at a dose of 25 kGy.
In Vitro Oxidative Stress Coculture Model. Human osteoblast like
cells MG63 (OB, Istituto Zooproﬁlattico Sperimentale IZSBS,
Brescia, Italy) and human osteoclast precursor 2T 110 (OC, Poietics
Osteoclast Precursor Cell System, Lonza Walkersville, Inc., MD,
USA) were used for the coculture model.
The coculture model was set up according to the following
indications: preosteoclasts were plated at a concentration of 3 × 104
cells/well in the bottom of 24 well plates leaving a little central empty
space. They were fed for 7 days with DMEM additioned with
macrophage colony stimulating factor (MCSF, 25 ng/mL) and
receptor activator for κB factor ligand (RANKL, 30 ng/mL) in
standard condition, at 37 ± 0.5 °C with 95% humidity and 5 ± 0.2%
CO2 to activate cell diﬀerentiation. In the meantime, osteoblasts were
expanded in DMEM supplemented with 10% FCS, 1% antibiotics
(100 U/mL penicillin, 100 μg/mL streptomycin), β glycerophosphate
(10−4 M), and ascorbic acid (50 μg/mL). After 6 days, OB were
counted, seeded at a concentration of 2 × 104 cells/well onto
biomaterial samples (ZnHA, ZnHAPEI, ZnHABP, ZnHAPEIBP) in
their own diﬀerentiation medium (DMEM supplemented with 10%
FCS, 1% antibiotics (100 U/mL penicillin, 100 μg/mL streptomycin),
β glycerophosphate (10−4 M), and ascorbic acid (50 μg/mL)) and
allowed to adhere for 24 h. Then, samples seeded with osteoblasts
were placed in the empty space of the well containing diﬀerentiating
osteoclasts (Scheme S2). When cells were cultured together, a mix of
medium was used, according to cell concentration proportion.
Cocultures with materials (ZnHA+, ZnHAPEI+, ZnHABP+,
ZnHAPEIBP+) were treated with 0.3 mM H2O2 for 48 h. The
ZnHA group was not treated with H2O2 and was used as a reference.
After 48 h, the medium was renewed with fresh medium without
H2O2 in all cultures that were maintained in standard conditions up to
7 days.
Cell Viability and Morphology. To assess viability of OB and OC
separately, cocultures were disassembled, and material samples with
OB were transferred to empty wells. WST1 colorimetric reagent test
(Roche Diagnostics GmbH, Manheim, Germany) was performed at 3
and 7 days of coculture. The assay is based on the reduction of
tetrazolium salt to a soluble formazan salt by a reductase of the
mitochondrial respiratory chain, active only in viable cells. A total of
100 μL of WST1 solution and 900 μL of medium (ﬁnal dilution:
1:10) were added to wells containing OC or materials with OB, and
the multiwell plates were incubated at 37 °C for the next 4 h.
Supernatants were quantiﬁed spectrophotometrically at 450 nm with a
reference wavelength of 625 nm. Results of WST1 are reported as
optical density (OD) and directly correlated with the cell number.
Random material samples of all groups were stained with the Live/
Dead assay (Molecular Probes, Eugene, OR, USA), according to the
manufacturer’s instructions to detect osteoblast colonization of
samples. Samples were visualized using an inverted microscope
equipped with an epiﬂuorescence setup (Eclipse TiU, NIKON
Europe BV, NITAL SpA, Milan, Italy): excitation/emission setting of
488/530 nm to detect green ﬂuorescence (live cells) and 530/580 nm
to detect red ﬂuorescence (dead cells).
Tartrate resistant acid phosphatase (TRAP) staining was
performed to assess osteoclast diﬀerentiation starting from mono
nucleated cells, according to manufacturer’s instructions (Sigma,
Buchs, Switzerland). The positive cells are multinucleated cells (three
or more nuclei for each cell) and developed red color of diﬀerent
intensities. Osteoclastogenesis was evaluated by counting the number
of TRAP positive cells, under the microscope by a semiautomatic
software (NIS Elements AR 4.30.01). Results are given as the
percentage of diﬀerentiated OC considering ZnHA− as reference
(100%).
Immunoenzymatic Assay. At the end of experimental time, the
supernatant was collected from all wells and centrifuged to remove
particulates, if any. Aliquots of supernatant were dispensed in
Eppendorf tubes for storage at −70 °C and assayed with the
following immunoenzymatic kits: alkaline phosphatase (ALP),
CloudClone Corp., Wuhan, China), collagen type I (COLL1,
CloudClone), osteoprotegerin (OPG, CloudClone), receptor activa
tor for nuclear factor KB ligand (RANKL, CloudClone).
qPCR. Total RNA was extracted from all samples at the end of
experimental time using the PureLink RNA mini kit (Life
Technologies, Carlsbad, CA, USA). Puriﬁed RNA was reverse
transcribed with the Superscript VILO cDNA synthesis kit
(Invitrogen, Life Technologies, Carlsbad, CA, USA), following
manufacturer’s instructions. Each sample (10 ng) was tested in
duplicate. qPCR analysis was performed in a LightCycler instrument
(Roche Diagnostics GmbH, Mannheim, Germany) using the
QuantiTect SYBR Green PCR kit (Qiagen, Hilden, Germany). The
protocol included a denaturation at 95 °C for 15 s, 40 cycles of
ampliﬁcation (95 °C for 15 s, appropriate annealing temperature for
each target as detailed in Table S1 for 20 s, a ﬁnal extension at 72 °C
for 20 s), and a melting curve to check for amplicon speciﬁcity. The
threshold cycle was used for the calculation of relative expression by
means of the 2 ΔΔCt method against GAPDH as the reference gene,
and ZnHA− samples as the calibrator. Studied genes are summarized
in Table S1.
Statistical Analysis. Statistical evaluation of in vitro biological tests
data was performed using the software package SPSS/PC+ Statistics
23.0 (SPSS Inc., Chicago, IL USA). The results presented are the
mean of six independent values. Data are reported as mean ±
standard deviation (SD) at a signiﬁcance level of p < 0.05. After
normal distribution and homogeneity of variance were veriﬁed, a one
way ANOVA was done for comparison between groups, and a post
hoc multiple comparison test was performed to detect signiﬁcant
diﬀerences among groups for the ELISA test and qPCR.
■ RESULTS AND DISCUSSION
Characterization of the As-Prepared Supports. The X
ray diﬀraction pattern of ZnHA shows a number of reﬂections
which indicate the presence of a unique crystalline apatitic
phase (Figure 1). The reduced values of the calculated lattice
constants (Table 1) in comparison to those of pure HA
synthesized with the same procedure (a = 9.4378(3) Å, c =
6.8862(2) Å) are in agreement with a partial substitution of
the smaller zinc ion (ionic radius = 0.074 nm) to the calcium
ion (ionic radius = 0.099 nm) in the hydroxyapatite
structure.26 Zn incorporation amounts to about 8 atom %, as
determined by ICP analysis and provokes a slight broadening
of the diﬀraction peaks that hinders the complete resolution of
the characteristic three peaks of HA centered at about 32° of
2θ, as well as of further peaks.
The line broadening of the (002) and (310) peaks was used
to evaluate the size of the coherently scattering domains (τhkl)
as derived from the Scherrer equation, on the hypothesis of
negligible microstrains. The results are reported in Table 1,
where τ002 is related to the mean crystallite size along the c axis,
whereas τ310 refers to the mean crystallite size along a direction
perpendicular to it. In agreement with previous results, the
values are signiﬁcantly smaller than those reported for HA in
the literature and support the known inhibitory role of zinc on
hydroxyapatite crystal growth.19,27,28
ZnHAPEI was obtained by the immersion of as prepared
ZnHA nanocrystals into a PEI solution. To this aim, we used
low molecular weight PEI, which was previously shown not to
give any osteoblast cytotoxic reaction.29,30 PEI content of
ZnHAPEI is 5.9 wt %, as determined through thermogravi
metric analysis from the weight loss centered at about 400 °C
of the thermogravimetric plot and due to PEI combustion
(Figure S1). PEI adsorption does not signiﬁcantly aﬀect the
structural parameters of the inorganic phase: in agreement with
the similar X ray diﬀraction patterns (Figure 1), both the
values of the lattice constants and of the size of coherently
scattering domains of ZnHAPEI are close to those of ZnHA
(Table 1). Moreover, PEI does not modify the morphology
and the speciﬁc surface area of the apatitic crystals (Figure S2,
Table 1). These results are not surprising in view of the low
molecular weight of PEI and of the procedure utilized to
functionalize the apatitic crystals with the polymer. In fact, PEI
was not introduced into ZnHA synthesis protocol, but it was
adsorbed on presynthesized crystals, mostly on their surface.
The adsorbed PEI is distributed on a relatively high speciﬁc
surface area (Table 1), which is not signiﬁcantly aﬀected by the
presence of the low molecular weight polymer. In agreement,
previously reported data showed that adsorption of a polymer
with a similar low molecular weight did not modify the surface
of calcium phosphate crystals, at variance with that observed
for the high molecular weight polymer.31 On the other hand,
the presence of the polycationic polymer on the surface of the
ZnHAPEI crystals signiﬁcantly modiﬁes the zeta potential
which assumes a positive and signiﬁcantly high value (Table
1).
Raman spectra of ZnHA and ZnHAPEI (Figure S3) show
the ν1 (960 cm
−1), ν2 (430−460 cm−1), ν3 (1030−1080 cm−1),
and ν4 (580−610 cm−1) characteristic bands of the apatitic
phosphate groups, and the vibration of the apatitic OH band at
3571 cm−1.32 Whereas the apatitic vibrations are not aﬀected
by the presence of PEI on the mineral surface, changes are
observed for the organic vibration bands in the Raman
spectrum. Slight shifts are detected in the domain of CH2
wagging and twisting motions especially at 1306 cm−1. The
asymmetric (νas) and symmetric (νs) C−H stretching vibration
bands, which appear at 2935 and 2866 cm−1 for the standard
PEI, are shifted downward and upward respectively for
ZnHAPEI sample, suggesting a conformational change of the
polymer when adsorbed on the apatitic surface.33 Moreover,
the decrease of the νs/νas intensity ratio can be related to the
order/disorder character of a polyethylene chain.33
Risedronate Adsorption Experiments. The adsorption
isotherms of risedronate on Zn substituted hydroxyapatite
(ZnHA) and PEI modiﬁed Zn substituted hydroxyapatite
(ZnHAPEI) at pH 7.4 and 37 °C are presented in Figure 2;
they represent the evolution of the amount of risedronate
adsorbed on the solids, Qads (μmol/m
2), as a function of the
BP equilibrium concentration in solution, Ceq. In agreement
Figure 1. Powder X ray diﬀraction patterns of as prepared apatitic
supports.
Table 1. Lattice Parameters, Coherent Lengths (τhkl) of the Perfect Crystalline Domains in the Direction Normal to (002) and
to (310), Planes Speciﬁc Surface Area (SSA), Zeta Potential, PEI, and Zn Contents of the Diﬀerent Apatitic Supports
a (Å) c (Å) τ002 (Å) τ310 (Å) SSA (m
2/g) zeta potential (mV) PEI content (wt %) Zn content (atom %)
ZnHA 9.4241(9) 6.8696(2) 367(4) 148(3) 86 15.3 7.9
ZnHAPEI 9.4238(5) 6.8691(4) 365(5) 152(4) 86 +30.9 5.9 7.9
with previous data,19 the isotherm obtained for ZnHA is a
Langmuirian type (r2 = 0.94).
The plateau was reached at relatively low equilibrium
concentrations of BP (below 1 mM), indicating a high aﬃnity
of risedronate for these apatitic surfaces, as observed in the
literature for the adsorption of bisphosphonate molecules on
various apatitic supports.18 The parameters of adsorption can
be determined from the Langmuir equation for ZnHA: the
maximum amount of adsorbed risedronate N and the aﬃnity
constant of risedronate for the solid surface K are equal to 1.20
± 0.08 μmol/m2 and 7 ± 1 L/mmol, respectively.
For ZnHAPEI mineral organic support, the amount of BP
molecules adsorbed was higher than on ZnHA, but the curve
does not reach a plateau even at a high equilibrium
concentration of BP in solution. The isotherm of risedronate
adsorption on ZnHAPEI cannot be described by the Langmuir
model (as the curve ﬁtting with Langmuir equation model
gives a low adjusted correlation coeﬃcient, r2 = 0.73, and a
high standard error for the aﬃnity constant K) but is better
ﬁtted with the Freundlich model (r2 = 0.81):
=Q KC nads eq (2)
where n and K are the Freundlich constants; the values of n
and K obtained for ZnHAPEI support are close to 0.21 ± 0.04
and 1.5 ± 0.2 μmol/m2, respectively. Freundlich model was
also found in the literature to well describe the adsorption of
organic molecules, such as uric acid, for example, on PEI
composites.34 Freundlich model is based on several assump
tions, including nonequivalent adsorption sites and low
interaction adsorbate/surface.
The variation of phosphate ions (PO4
3−) concentration
released in solution from the diﬀerent apatitic supports during
adsorption is presented in Figure 3a as a function of adsorbed
risedronate amount. For ZnHA support, the amount of
phosphate ions released in solution increased linearly as a
function of the amount of adsorbed BP. We can observe that
the increase of released phosphate from ZnHAPEI support
during adsorption of BP is much less signiﬁcant, and the
amount of released phosphate in solution remained low (about
0.5 mM) and appears not to be correlated with the amount of
adsorbed risedronate, suggesting diﬀerent mechanisms of
adsorption for these two functionalized apatitic supports.
The low release of phosphate ions is probably mainly due to
the slight dissolution of the apatitic substrate during the release
experiment. The mechanism of chemisorption by ion exchange
process between phosphate groups of the apatitic surface and
bisphosphonate in solution, described in many studies for the
adsorption of biomolecules or drugs such as bisphosphonates
on apatitic supports,17,18 seemed not relevant for this mineral
organic ZnHAPEI support. It suggests the contribution of
another mechanism in the case of such PEI functionalized
apatitic support, especially physisorption associated with the
presence of PEI coating on this composite support. The
contribution of chemisorption on apatitic surface and
physisorption on PEI coating resulted in a greater BP
adsorption content compared with ZnHA mineral support
for all the points of the isotherm (Figure 2).
The slight dissolution of the supports during the adsorption
experiments is conﬁrmed by the small amounts of calcium and
zinc ions measured in the supernatants after BP adsorption: the
concentrations of both cations were less than 0.5 mM for
ZnHA and less than 2 mM for ZnHAPEI.
Characterization of the Materials after Risedronate
Uptake. The comparison of TEM images of ZnHABP and
ZnHAPEIBP with those of ZnHA and ZnHAPEI reported in
Figure 4 shows that the morphologies of the substrates after
risedronate adsorption are not signiﬁcantly diﬀerent from those
of the as prepared apatitic samples. In agreement, the
Figure 2. Adsorption isotherms of risedronate on Zn substituted
hydroxyapatite (ZnHA) and PEI modiﬁed Zn substituted hydrox
yapatite (ZnHAPEI) at pH 7.4 and 37 °C. The ZnHA and ZnHAPEI
data are ﬁtted with a Langmuir and a Freundlich isotherm,
respectively.
Figure 3. (a) Concentration of phosphate ions released in solution
after BP adsorption as a function of the concentration of risedronate
adsorbed on the powders, ZnHA and ZnHAPEI (1 mM KCl aqueous
solution at pH 7.4 and 37 °C). (b) Risedronate released (wt %) from
ZnHABP and ZnHAPEIBP supports as a function of time.
adsorption of risedronate does not provoke any modiﬁcation in
the value of the speciﬁc surface area.
The results of XRD analysis also indicate that the adsorption
of risedronate does not alter the crystallinity of the apatitic
samples and does not provoke precipitation of any other
crystalline phase (Figure S4). ZnHAPEIBP displays a slightly
reduced value of zeta potential in comparison to ZnHAPEI
(+27.6 mV vs +30.9 mV, respectively), in agreement with the
negative charge of risedronate, which interacts with the
polycationic polymer. At variance, the value of zeta potential
of ZnHA is negative (Table 1) and does not change
signiﬁcantly after risedronate adsorption in ZnHABP (−15.0
mV for ZnHABP vs −15.3 mV for ZnHA).
After adsorption of risedronate, Raman spectra of ZnHABP
and ZnHAPEIBP display additional bands characteristic of the
presence of BP: pyridine and phosphonate groups vibration
bands are observed, as shown in Figure S5 for ZnHABP.
However, ZnHABP Raman spectrum shows some changes in
the vibration domains of the characteristic bands of BP
compared to those of risedronate sodium salt: especially,
broadening and shift of the phosphonate vibration bands at
802 and 863 cm−1, the pyridine ring vibration bands (3000−
3100 cm−1), and also ν(C−H) stretching (2900−3000 cm−1),
ν(CN) and ν(CC) stretching (1450 and 1600 cm−1).35
As no additional phase has been observed by XRD and TEM
observations, these Raman spectroscopy results suggest a
strong interaction between BP and calcium on the apatitic
surface, in accordance with the Langmuir model proposed for
the adsorption process on ZnHA. Similar shifts of the
characteristic bands of risedronate are also observed in
Raman spectrum of ZnHAPEIBP compared with the BP free
molecule (data not shown), with very small diﬀerences
compared with the ZnHABP spectrum. No diﬀerence was
observed for the position and intensity of the vibration bands
of the PEI macromolecule on ZnHAPEI and ZnHAPEIBP
spectra, indicating that PEI was still on the HA surface after BP
adsorption experiments and can participate in the process of
adsorption of BP.
BP Release Experiments. The kinetics of risedronate
release from the diﬀerent apatitic supports are presented in
Figure 3b. For all the samples, the quantity of released
risedronate represents a small percentage of the initial
adsorbed amount, in accordance with the results observed in
the literature for BPs released from apatitic supports.18 The
total amount of risedronate released was higher from ZnHABP
(about 9%) than from ZnHAPEIBP (about 3%).
The release from ZnHABP support was fast during the ﬁrst
hour and then slowed down. Therefore, it cannot be described
by a simple Higuchi diﬀusion model (r2 = 0.83 for
ZnHABP),36 due also to the partial dissolution of the apatitic
support occurring at the same time.18,19 Risedronate molecules
were irreversibly adsorbed by an ion exchange process on the
apatite supports, and the adsorbed species cannot be removed
from the apatitic surface by simple dilution or washing of the
solids, as previously demonstrated for biomolecules or drugs
such as bisphosphonates adsorbed on apatitic surfaces.18
In contrast, as reported by some authors, a fast release by a
simple diﬀusion process can be observed from the pure
polymeric matrix such as PEI,37 which can completely release
drugs by penetration of the liquid and chains swelling. Indeed,
for ZnHAPEIBP composite support, the release kinetic
reached a plateau within a few minutes (Figure 3b), which is
in accordance also with the proposed Freundlich adsorption
model. However, no more than 3% of the initial quantity of BP
adsorbed on ZnHAPEIBP was released after 30 min, and no
more release was observed at the end of 3 days, despite the
relatively higher quantity of risedronate adsorbed on
ZnHAPEIBP compared with ZnHABP. No diﬀerence in the
speciﬁc surface area was observed between ZnHABP and
ZnHAPEIBP that could explain such a low release. Thus,
risedronate release from the ZnHAPEIBP support is not
controlled by simple diﬀusion (r2 = 0.24) as generally observed
from pure polymeric matrix such as branched PEI,37 or from
PEI modiﬁed hydroxyapatite (HAPEI).19 In particular, the
small amount of BP release from ZnHAPEIBP in comparison
to that previously reported for HAPEIBP19 can be related to
the diﬀerent methods of preparation of the supports:
adsorption from solution, utilized for the synthesis of
ZnHAPEI, leads to a signiﬁcantly higher polymer content
(5.9 wt %) than coprecipitation (2.9 wt %) utilized for
HAPEI.19 The higher content of the polycationic polymer on
ZnHAPEI compared with HAPEI should enhance interaction
with the negatively charged risedronate, promoting BP
adsorption and limiting BP release.
This short term release study was implemented to compare
and model the ﬁrst hours of risedronate release from the two
apatitic supports, especially in order to study the inﬂuence of
the presence of PEI, in a simple medium at pH 7.4 and 37 °C.
Interestingly, no burst release was observed, which is a good
point for the development of such apatitic local drug delivery
systems able to have an eﬀect on osteoclastogenesis and bone
resorption.
In Vitro Tests. In vitro tests were performed on disk
shaped samples, which were prepared by pressing the powders
of the diﬀerent materials. Cells response is greatly inﬂuenced
by the topography of the samples.38 Therefore, it is important
to check and control the roughness of the surface of the
samples prepared for in vitro tests. To this aim, surface
Figure 4. TEM images of the supports after (ZnHABP and ZnHAPEIBP) risedronate adsorption. Magniﬁcation in all TEM images is the same for
direct comparison.
investigation of the disks was performed through AFM analysis
(Figure 5). The results indicated similar values of roughness
parameters, arithmetic mean roughness (Ra), root square
roughness (Rq), and the vertical distance between the highest
and lowest points within the evaluation length (Rt), for all
tested samples. Indeed, the average values recorded are Ra =
0.017 ± 0.002 μm, Rq = 0.023 ± 0.002 μm, and Rt = 0.195 ±
0.008 μm for ZnHA disks (composed from the starting
powders without further functionalization), and Ra = 0.025 ±
0.002 μm, Rq = 0.031 ± 0.003 μm, and Rt = 0.233 ± 0.013 μm
for ZnHAPEIBP samples.
Cell Viability and Morphology. Oxidative stress is
involved in numerous pathologies, including osteoporosis,
because of its role in bone turnover. In this study cocultures
were treated with 0.3 mM H2O2 for 48 h in order to study the
eﬀect of risedronate presence on cell behavior in an
unfavorable microenvironment, simulating oxidative stress.
Viability was studied at 3 and 7 days on experimental treated
groups (ZnHA+, ZnHAPEI+, ZnHABP+, ZnHAPEIBP+) and
compared to treated (HA+) and untreated (HA−, ZnHA−)
reference groups and OB or OC monolayer without materials
(CTR , CTR+). A signiﬁcant diﬀerence in osteoblast viability
after both 3 and 7 days of culture can be observed between
treated groups CTR+, HA+, ZnHA+, ZnHAPEI+, ZnHA
PEIBP+ and the reference group CTR−, HA−, ZnHA−
(Table S2). On the contrary, osteoblast viability is signiﬁcantly
enhanced in the ZnHABP+ group (Figure 6) when compared
to other treated groups, and ZnHAPEIBP+ when compared to
ZnHA+, indicating that the presence of risedronate allows
recovery of impairment due to the oxidative stress conditions
created in vitro. Representative images of osteoblasts grown
onto material samples, shown in Figure 6, conﬁrm the optical
density values obtained by the WST1 test.
Osteoclast viability on CTR, HA, and ZnHA both at 3 and 7
days does not diﬀer signiﬁcantly when treated (+) and
untreated (−) groups were compared (Table S2, Figure 6),
showing that H2O2 treatment does not aﬀect osteoclast
viability, in agreement with previous results.39 At variance,
the presence of PEI and/or BP signiﬁcantly decreases
osteoclast viability, suggesting an inhibitory role of both
functionalizing agents.
Cell Activity. Bioactivity of cocultured osteoblasts was
assessed by evaluation of the most common markers of
osteoblast diﬀerentiation, by measuring both protein produc
tion and gene expression. As shown in Figures 7a−c and S6,
the results of the immunoenzymatic assays demonstrate that
Figure 5. Atomic force microscopy images of the surfaces of disk
shaped samples obtained by pressing as prepared ZnHA and
ZnHAPEIBP powders into cylindrical molds and used for cell tests.
Figure 6. Osteoblast and osteoclast viability by the WST1 test after 7 days of coculture on material samples in oxidative stress environment (ZnHA
+, ZnHAPEI+, ZnHABP+, ZnHAPEIBP+) and reference (ZnHA−). Statistical analysis is reported in the ﬁgure (*p < 0.05, **p < 0.005, ***p <
0.0005). Live & Dead staining of OB cultured onto samples. Images appeared consisting with WST1 values. Magniﬁcation in all the images is the
same, bar = 200 μm. OB: ***ZnHA− vs ZnHA+, ZnHAPEI+, ZnHABP+, ZnHAPEIBP+; ***ZnHABP+ vs ZnHA+, ZnHAPEI+, ZnHAPEIBP+;
* ZnHAPEIBP+ vs ZnHA+; OC: ***ZnHA−, ZnHA+ vs ZnHAPEI+, ZnHAPEIBP+; **ZnHA−, ZnHA+ vs ZnHABP+.
the values of ALP, COLL1, and OPG produced by osteoblasts
grown on ZnHA+ are signiﬁcantly lower than those measured
for ZnHA−. On the contrary, RANKL in the ZnHA+ group is
signiﬁcantly higher than in ZnHA−, causing a signiﬁcant
reduction of the OPG/RANKL ratio of ZnHA+ in comparison
to ZnHA−. OPG and RANKL are expressed by osteoblasts
and are known to be essential for regulating osteoclast
diﬀerentiation.40
The impairment due to in vitro created oxidative stress is
not recovered in the samples containing PEI, which show
values of osteoblast diﬀerentiation markers similar to those
measured for ZnHA+. On the contrary, the activity of OB is
signiﬁcantly improved in the presence of risedronate, so that it
brings the activity of ZnHABP+ group back to the normal
reference level: the measured values of ALP and OPG reach
those obtained in the reference group ZnHA−, with no
signiﬁcant diﬀerences between ZnHABP+ and ZnHA−.
COLL1 is signiﬁcantly higher in ZnHABP+ than in all other
groups, including the reference one, whereas the OPG/
RANKL ratio assumes the highest value on ZnHABP+, which
is signiﬁcantly diﬀerent for both ZnHA− and ZnHA+.
Therefore, risedronate stimulates the activity of the OB even
in an unfavorable situation as in the presence of oxidative
stress/aging, showing a behavior similar to that previously
reported for alendronate.39 The reduction of the negative
eﬀects of H2O2 on viability and activity of OB induced by
risedronate in ZnHABP+ is less evident when PEI is also
present on the sample surface: OB viability on ZnHAPEIBP+
is lower than on ZnHABP+, although higher than on ZnHA+,
whereas ALP and COLL1 values on ZnHAPEIBP+ are not
signiﬁcantly diﬀerent from those for ZnHA+.
The statistical evaluation of gene expression of the same
parameters of OB activity measured by immunoenzymatic
assays is consistent with the results shown above (Figure 7d−
Figure 7. Immunoenzymatic assay on supernatant (a−c) and gene expression (d−f) of cocultured OB on material ZnHA+, ZnHAPEI+, ZnHABP
+, and ZnHAPEIBP+ in oxidative stress conditions and reference (ZnHA−) after 7 days of incubation. ELISA tests data were normalized to WST1
values. Gene expression data were normalized to GAPDH expression and presented as fold change relative to the reference group, considered as 1.
Results are the mean (± sd) of six replicates. Statistical analysis is reported in the ﬁgure (*p < 0.05, **p < 0.005, ***p < 0.0005). (a) ALP:
*ZnHA−, ZnHABP+ vs ZnHA+, ZnHAPEI+, ZnHAPEIBP+. (b) COLL1: *ZnHA− vs ZnHA+; *ZnHABP+ vs ZnHA−, ZnHA+, ZnHAPEI+,
ZnHAPEIBP+; (c) OPG/RANKL ratio: *ZnHABP+ vs ZnHA−; *ZnHA+ vs ZnHA−, ZnHABP+, ZnHAPEIBP+; (d) ALPL: ***ZnHABP+ vs
ZnHA−, ZnHA+, ZnHAPEI+, ZnHAPEIBP+; ***ZnHA− vs ZnHA+, ZnHAPEI+, ZnHAPEIBP+; * ZnHAPEIBP+ vs ZnHAPEI+; (e) COL1A1:
***ZnHA− vs ZnHA+, ZnHAPEI+, ZnHABP+, ZnHAPEIBP+; ***ZnHABP+ vs ZnHA+, ZnHAPEI+, ZnHAPEIBP+; **ZnHAPEIBP+ vs
ZnHA+, ZnHAPEI+; (f) OPG: ***ZnHABP+ vs ZnHA−, ZnHA+, ZnHAPEI+, ZnHAPEIBP+; ***ZnHA− vs ZnHA+, ZnHAPEI+,
ZnHAPEIBP+; ***ZnHA+ vs ZnHAPEI+, ZnHAPEIBP+; RANKL: ***ZnHA− vs ZnHA+, ZnHAPEI+, ZnHABP+; **ZnHABP+ vs ZnHA+,
ZnHAPEI+; ***ZnHAPEIBP+ vs ZnHA+, ZnHAPEI+.
f). The presence of risedronate increased ALPL and COL1A1
gene expression in both ZnHABP+ and, even if to a lesser
amount, on ZnHAPEIBP+. Also OPG and RANKL expression
demonstrated to be in line with immunoenzymatic assays,
results showing in particular a signiﬁcant higher expression of
OPG for ZnHABP+ when compared to all other groups.
The less beneﬁcial eﬀect exerted by risedronate on
osteoblast viability and diﬀerentiation in the PEI functionalized
sample, ZnHAPEIBP, might be related to its reduced extent of
release in comparison to that measured from ZnHABP (Figure
3b). In the examined conditions, the percentage of risedronate
released from ZnHABP is more than twice that released from
ZnHAPEIBP. Although the conditions utilized for measure
ment of risedronate release proﬁle were quite diﬀerent from
those of the cell culture environment, it is conceivable to
hypothesize that also during in vitro experiments the amount
of risedronate released from ZnHAPEIBP was less than from
ZnHABP and possibly too small to allow complete recovery
from the negative eﬀects of H2O2 treatment on osteoblasts.
On the other hand, both PEI and risedronate aﬀect
osteoclast activity. The expression of cathepsin K (CTSK),
which is secreted by active osteoclasts and is a promoter of
bone resorption,41 was measured in order to evaluate the
degree of osteoclast diﬀerentiation. The results, reported in
Figure 8, show that oxidative stress provokes an increase in the
expression of CTSK, which reaches its highest level on ZnHA
+. The level is slightly less on ZnHAPEI+, whereas it is
signiﬁcantly reduced on ZnHABP+ and ZnHAPEIBP+, in
agreement with an inhibitory role of risedronate on osteoclast
activity. Moreover, the results of TRAP staining show that
osteoclast formation by monocytes is not aﬀected by H2O2
treatment. TRAP staining displays a reduced value on
ZnHAPEI+, indicating that PEI, in addition to signiﬁcantly
reducing the number of OC, also partially reduces OC
diﬀerentiation. However, the major role is played by
risedronate, which lowers both OC diﬀerentiation, as stated
by the drastically reduced expression of CSTK and TRAP
positive cells, and OC number, through a direct action on
osteoclast viability as well as an osteoblast mediated regulation
of OPG/RANKL pathway.
■ CONCLUSIONS
The bifunctionalized hydroxyapatite obtained in this work
contains about 8 atom % of zinc substituted to calcium ions
and about 5.9 wt % PEI loaded on the nanocrystals surface.
The presence of PEI does not alter the structural and
morphological characteristics of ZnHA but signiﬁcantly
increases the value of the zeta potential and promotes
risedronate adsorption. In fact, the amount of adsorbed
risedronate is higher on ZnHAPEIBP than on ZnHABP. The
isotherm of the bisphosphonate adsorption on ZnHAPEI can
be ﬁtted with the Freundlich model (r2 = 0.81), at variance
with the adsorption on ZnHA which follows a Langmuir type
isotherm (r2 = 0.94). Moreover, phosphate release in solution
from the ZnHAPEI support is not aﬀected by the amount of
adsorbed risedronate, suggesting that the mechanism of
adsorption on ZnHAPEI is diﬀerent from that described in
the literature as an ion exchange process between phosphates
on the apatitic surface and bisphosphonate in solution.17,18
The strong interactions between the polycationic polymer and
the negatively charged bisphosphonate can explain the much
smaller quantity of risedronate released from ZnHAPEIBP
than from ZnHABP. Both materials exhibit slow risedronate
release proﬁles as required for antiresorptive bone substitute
materials involving local and sustained drug delivery.
The results of in vitro cell tests carried out using a coculture
model reveal a novel characteristic of risedronate: the data
obtained on the diﬀerently functionalized samples indicate that
risedronate presence counteracts the negative eﬀects of H2O2,
which is added to the culture medium to simulate conditions
of oxidative stress, and enhances osteoblast viability and
activity. The beneﬁcial eﬀect of risedronate on osteoblasts is
slightly reduced in the PEI containing samples (ZnHAPEIBP).
However, PEI contributes to lower osteoclast number and
diﬀerentiation, as shown by CTSK and TRAP staining results.
It follows that the best choice for local applications aimed to
downregulate the excessive resorption activity of osteoclasts
and/or to protect osteoblasts from an undesired increase of
reactive oxygen species can be ZnHAPEIBP or ZnHABP,
depending on the kinetics of bone metabolism.
Figure 8. Gene expression of CTSK (a) and TRAP staining (b) of
cocultured OC on material ZnHA+, ZnHAPEI+, ZnHABP+, and
ZnHAPEIBP+ in oxidative stress conditions and reference (ZnHA−)
after 7 days of incubation. The expression of CTSK was normalized to
GAPDH expression and presented as fold change relative to the
ZnHA− reference group, considered as 1. Results are the mean (±
sd) of six replicates. Statistical analysis is reported in the ﬁgure (*p <
0.05, **p < 0.005, ***p < 0.0005). Diﬀerentiated OC after TRAP
staining were quantiﬁed by counting the number of TRAP positive
cells in six ﬁelds each group, under the microscope (4×) by a
semiautomatic software (NIS Elements AR 4.30.01), and the
percentage is reported in the ﬁgure, considering ZnHA− as a
reference (100%). Magniﬁcation in all the images is the same, bar =
200 μm. CTSK: ***ZnHA+, ZnHAPEI+ vs ZnHA−, ZnHABP+,
ZnHAPEIBP+; **ZnHA+ vs ZnHAPEI+; ***ZnHA− vs ZnHAPEI
+, ZnHABP+. TRAP: *** ZnHA−, ZnHA+ vs ZnHAPEI+, ZnHABP
+, ZnHAPEIBP+.
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Scheme S1. Molecular structures of polyethylenimine (PEI) and risedronate. 
 
 
 
 
                                Scheme S2. Scheme of cell seeding for the co-culture model 
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Figure S1 – Thermogravimetric plot of ZnHA and ZnHAPEI. The weight loss centered at 
about 400°C is due to the combustion of organic fraction and allows to determine that 
ZnHAPEI sample contains about 5.9 wt% PEI. 
 
 
 
Figure S2 – TEM images of the supports ZnHA and ZnHAPEI before risedronate 
adsorption. Magnification in all TEM images is the same for direct comparison. 
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Figure S3 – Raman spectra of ZnHA (a), ZnHAPEI (b), PEI (c). The two insets focus on two 
spectral domains (1150-1650 cm-1 and 2550-3850 cm-1) showing especially the main 
characteristic vibration bands for CH and CH2 groups in PEI molecule. 
 
 
Figure S4 – X-ray diffraction patterns of ZnHABP and ZnHAPEIBP. The adsorption of 
risedronate does not alter the crystallinity of pristine apatitic substrates and does not provoke 
precipitation of any other crystalline phase. 
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Figure S5 – Raman spectra of ZnHA (a), ZnHABP (b), risedronate (BP) sodium salt 
(c). The insets focus each on a spectral domain (775-925 cm-1, 1375-1675 cm-1 and 
2700-3300 cm-1) to show the main characteristic vibration bands of risedronate 
molecule (pyridine ring, phosphonate group, C-H, C=C and C=N groups). 
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Figure S6 – OPG and RANKL levels on supernatant of ZnHA+, ZnHAPEI+, ZnHABP+, 
ZnHAPEIBP+ materials cultured with osteoblasts and osteoclasts in oxidative stress conditions and 
reference (ZnHA-) after 7 days of incubation. Statistical analysis is reported in the figure (*p < 
0.05). 
OPG: *ZnHA-, ZnHABP+ vs ZnHA+, ZnHAPEI+, ZnHAPEIBP+; 
RANKL: *ZnHA- vs ZnHAPEI+, ZnHABP+; *ZnHA+ vs ZnHAPEI+, ZnHABP+, 
ZnHAPEIBP+. 
 
 
 
Table S1. Specifications of primer used for qPCR analysis. 
 
GENE Primer forward Primer reverse Amplicon Lenght 
Annealing 
Temperature 
GAPDH 5’-TGGTATCGTGGAAGGACTCA-3’ 5’-GCAGGGATGATGTTCTGGA -3’ 123 bp 56°C 
ALPL QuantiTect Primer Assay (Qiagen) Hs_ALPL_1_SG 110 bp 55°C 
COL1A1 QuantiTect Primer Assay (Qiagen) Hs_COL1A1_1_SG 118 bp 55°C 
CTSK CAGACAACAGATTTCCATCAGC CTTCTTCCATAGCTCCCAGTG 118 bp 60°C 
OPG CTACCAAGACACTAAGCCAGT AAACAGTGAATCAACTCAAAAATGTG 113 bp 60°C 
RANKL TGAGATGAGCAAAAGGCTGAG AGGAGCTGTGCAAAAGGAAT 134 bp 60°C 
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Table S2. Viability of monolayer (CTR) and HA in normal (-) and under H2O2 (+) conditions  
together with other experimental groups at 3 and 7 days. 
Group WST1 assay OB 3 days OB 7 days OC 3 days OC 7 days 
CTR- 0.917+/-0.028 1.315+/-0.200 1.248+/-0.035 1.248+/-0.035 
HA- 0.807+/-0.039 1.262+/-0.018 1.281+/-0.078 1.279+/-0.023 
ZnHA- 0.838+/-0.048 1.368+/-0.067 1.255+/-0.036 1.227+/-0.104 
CTR+ 0.539+/-0.047a 0.678+/-0.041a 1.254+/-0.032 1.254+/-0.032 
HA+ 0.478+/-0.046a 0.585+/-0.016a 1.255+/-0.007 1.269+/-0.037 
ZnHA+ 0.585+/-0.024a 0.662+/-0.036a 1.200+/-0.048 1.222+/-0.076 
ZnHAPEI+ 0.559+/-0.023a 0.679+/-0.031a 0.840+/-0.056b 0.761+/-0.102b 
ZnHABP+ 0.773+/-0.033 1.085+/-0.054 0.821+/-0.023b 0.843+/-0.092b 
ZnHAPEIBP+ 0.641+/-0.019a 0.780+/-0.017a 0.753+/-0.031b 0.739+/-0.063b 
 
OB 3 and 7 days :  
a CTR+, HA+, ZnHA+, ZnHAPEI+, ZnHAPEIBP+ vs CTR-, HA-, ZnHA-, ZnHABP+ (p<0.0005) 
OC 3 and 7 days : 
 b ZnHAPEI+, ZnHABP+, ZnHAPEIBP+ vs all other groups (p<0.0005) 
 
